Skip to main content
Figure 2 | World Allergy Organization Journal

Figure 2

From: Section 3. A Discussion of Flexible Dosing and Patient-Centered Therapy: Highlights of the Asthma Summit 2009: Beyond the Guidelines

Figure 2

Time to first severe asthma exacerbation in patients treated with budesonide/formoterol (160/4.5 μ g bid, combination) plus as needed therapy with terbutaline (0.4 mg, n = 1138), formoterol (4.5 μ g, n = 1137), or the combination (SMART, n = 1107). All patients randomized were symptomatic on the maintenance combination therapy during a 2-week run-in. Reprinted from Rabe KF, Atienza T, Magyar P, Larson P, Jorup C, Lalloo UG: Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized controlled, double-blind study. Lancet. 2006;368: 744-753, with permission from Elsevier [10].

Back to article page

World Allergy Organization Journal

ISSN: 1939-4551

Contact us